小柯机器人

德国柏林洪堡大学Irina Lehmann等研究人员合作发现，高血压会延迟病毒清除并加剧COVID-19患者的气道炎症。 这一研究成果于2020年12月24日在线发表在国际学术期刊《自然—生物技术》上。

通过将临床数据（n=144）和气道样本的单细胞测序数据（n=48）与体外实验相结合，研究人员观察到高血压患者免疫细胞具有明显的炎性倾向，与关键的COVID-19进展相关。血管紧张素转化酶抑制剂（ACEI）治疗与COVID-19相关的过度炎症减弱和细胞内在抗病毒反应增强有关，而血管紧张素受体阻滞剂（ARB）治疗与上皮免疫细胞相互作用增强有关。

特别是在ARB治疗下，高血压患者的巨噬细胞和嗜中性粒细胞表现出促炎细胞因子CCL3和CCL4以及趋化因子受体CCR1的高表达。尽管这一队列的有限规模无法使研究人员确定临床疗效，但数据表明ACEI治疗高血压COVID-19患者的临床获益值得进一步研究。

据了解，在COVID-19中，高血压和心血管疾病是严重疾病进展的主要危险因素。但是，主要的抗高血压疗法（ACEI和ARB）会产生什么样的后果却并不清楚。

附：英文原文

Title: Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19

Author: Saskia Trump, Soeren Lukassen, Markus S. Anker, Robert Lorenz Chua, Johannes Liebig, Loreen Thrmann, Victor Max Corman, Marco Binder, Jennifer Loske, Christina Klasa, Teresa Krieger, Bianca P. Hennig, Marey Messingschlager, Fabian Pott, Julia Kazmierski, Sven Twardziok, Jan Philipp Albrecht, Jrgen Eils, Sara Hadzibegovic, Alessia Lena, Bettina Heidecker, Thore Brgel, Jakob Steinfeldt, Christine Goffinet, Florian Kurth, Martin Witzenrath, Maria Theresa Vlker, Sarah Dorothea Mller, Uwe Gerd Liebert, Naveed Ishaque, Lars Kaderali, Leif-Erik Sander, Christian Drosten, Sven Laudi, Roland Eils, Christian Conrad, Ulf Landmesser, Irina Lehmann

Issue&Volume: 2020-12-24

Abstract: In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies—angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)—remain unclear. Combining clinical data (n=144) and single-cell sequencing data of airway samples (n=48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial–immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation.

DOI: 10.1038/s41587-020-00796-1

Source: https://www.nature.com/articles/s41587-020-00796-1

Nature Biotechnology：《自然—生物技术》，创刊于1996年。隶属于施普林格·自然出版集团，最新IF：68.164
官方网址：https://www.nature.com/nbt/
投稿链接：https://mts-nbt.nature.com/cgi-bin/main.plex